Immix Biopharma interim NEXICART-2: 89% CR rate; MRD suggests up to 98% CR, BLA planned mid-2027

Immix Biopharma reported an 89% complete response rate (40/45) in the Phase 2 NEXICART-2 trial, with MRD-negativity in pending patients indicating a potential to reach up to 98% CR.Key Highlights:Original SEC Filing: Immix Biopharma, Inc. [ IMMX ] - 8-K - Sep. 29, 2026This is an AI-powered summary…